Pliant Therapeutics Inc (PLRX) - Total Liabilities
Based on the latest financial reports, Pliant Therapeutics Inc (PLRX) has total liabilities worth $76.29 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PLRX cash generation efficiency to assess how effectively this company generates cash.
Pliant Therapeutics Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Pliant Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check Pliant Therapeutics Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Pliant Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Pliant Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Inoue Rubber (Thailand) Public Company Limited
BK:IRC
|
Thailand | ฿1.18 Billion |
|
Gemvaxlink Co. Ltd
KQ:064800
|
Korea | ₩84.93 Billion |
|
Pylon Public Company Limited
BK:PYLON
|
Thailand | ฿328.92 Million |
|
Flag Ship Acquisition Corp. Unit
NASDAQ:FSHPU
|
USA | $2.93 Million |
|
Coeptis Therapeutics Inc
NASDAQ:COEP
|
USA | $3.26 Million |
|
Engenco Ltd
AU:EGN
|
Australia | AU$94.56 Million |
|
Epitomee Medical Ltd
TA:EPIT
|
Israel | ILA6.32 Million |
|
Brimag -L
TA:BRMG
|
Israel | ILA322.51 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Pliant Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Pliant Therapeutics Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pliant Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pliant Therapeutics Inc (2017–2024)
The table below shows the annual total liabilities of Pliant Therapeutics Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $92.87 Million | +140.73% |
| 2023-12-31 | $38.58 Million | +3.51% |
| 2022-12-31 | $37.27 Million | +68.22% |
| 2021-12-31 | $22.16 Million | +77.75% |
| 2020-12-31 | $12.46 Million | -89.57% |
| 2019-12-31 | $119.50 Million | +77.27% |
| 2018-12-31 | $67.41 Million | +2014.52% |
| 2017-12-31 | $3.19 Million | -- |
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral,… Read more